Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy

NCT03820817 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03820817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03820817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Completed
Start date
May 15, 2019
Completion date
November 30, 2025
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gammopathy igg, gammopathy, monoclonal, iga monoclonal gammopathy, igg monoclonal gammopathy, igm monoclonal gammopathy, light chain deposition disease, monoclonal gammopathy, smoldering waldenstrom macroglobulinemia, waldenstrom macroglobulinemia